Overview
Status
Active
Registry date
2015-01-08
Share capital
5,250.00 PLN
Registered address
ul. Dr. Stefana Kopcińskiego 69/71, 90-032 Łódź, Poland
Electronic delivery address
AE:PL-37723-98015-CBGSR-27
Financials
Revenue history
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 89 days for 2021).
- 202515/07/2026
- 202414/07/2025
- 202316/07/2024
- 202218/06/2023
- 202112/10/2022
- 202029/09/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 767.36MedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD -2.38kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 3.15kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 54.97kMedianUSD 608.93kAverageUSD 11.85m
Industry
Public procurement
No recorded participation in tenders.
Hammermed Medical Polska is the contractor in 2 public sector contracts, worth USD 335.27k in total. They were signed with 2 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Oct 15, 2026 | Catheter | $992.71 | Ginekologiczno - Położniczy Szpital Kliniczny Im. Heliodora Święcickiego Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu | |
| Aug 7, 2026 | Supply of stimulators | $334,279 | Uniwersytecki Szpital Kliniczny w Białymstoku |
Authorized Representatives
Piotr Radosław Hammer – President of the Management Board
Monika Iwona Jach – Attorney-in-fact (sole)
Manner of representation
Each member of the management board is authorised to make declarations of will on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Piotr Radosław Hammerage 60 | 104 | $1,404.65 | 99.0476% |
Others | 1 | $13.51 | 0.9524% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Novama CloudS.A. | $8,295,437.50 | novama.cloud | ||
| Euroleki Gksp. z o.o. + limited partnership | $6,866,421.91 | euroleki.eu | ||
| Ana-Medsp. z o.o. | $5,202,905.16 | ana-med.eu | ||
| TDFS.A. | $5,168,316.22 | tdfsa.pl | ||
| Orthoactivesp. z o.o. | $617,449.08 | orthoactive.pl | ||
| CanpolandS.A. | $328,824.15 | canpoland.com | ||
| Geneco Groupsp. z o.o. | $156,220.50 | genecocontact.pl | ||
| Novaova Sosnowski Wadowskisp. k. | $54,452.69 | novaova.pl | ||
| Endolink PharmaS.A. | $7,191.18 | endolink.pl | ||
| Novaovasp. z o.o. | $0.16 | novaova.pl |
Change history
| Date | Event | |
|---|---|---|
| 2016-06-29 | Share capital increase (5,000.00 PLN → 5,250.00 PLN) | |
| 2015-01-08 | Entered in the register |
FAQ
The main business activity of Hammermed Medical Polska focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on January 8, 2015.
The headquarters is located at: ul. Dr. Stefana Kopcińskiego 69/71, 90-032 Łódź.
The management board includes Piotr Radosław Hammer (President of the Management Board).
The share capital of the company is PLN 5,250 (approx. $1,418).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $767, representing a decrease of 6.6% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of $2,381. For comparison, in 2024 the loss was $2,316, meaning the company increased its loss by 2.6%.
The largest operating cost category falls under external services. This category amounted to $3,149 in 2025, representing 100% of all operating expenses.
Last updated: 2026-07-15